Navigation Links
Hopeful of Reduced Regulation, Biotech Stocks Stay the Course with Advanced Drug Developments
Date:1/19/2017

PALM BEACH, Florida, January 19, 2017 /PRNewswire/ --

While various reports indicate the incoming Trump administration appears serious about reducing the FDA's regulatory strictness as a way to boost advancements and innovation in the medical drug industry, many of the leading biotech and pharmaceutical companies forge ahead with new clinical trials and development of advanced drug treatments and therapies.  Biotechs and Pharma companies forging ahead with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: MBRX), Apricus Biosciences, Inc. (NASDAQ: APRI), CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE).

Moleculin Biotech, Inc., (NASDAQ: MBRX), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Drs. Sandra Silberman and Paul Waymack have joined the Company's Scientific Advisory Board (SAB). The Company's current SAB also includes Dr. Waldemar Priebe (Chair) and Dr. Madeleine Duvic. Read this and more news for Moleculin Biotech at http://marketnewsupdates.com/news/mbrx.html

Moleculin's Chairman and CEO, Walter Klemp, commented, "We are pleased to have attracted Drs. Sandra Silberman and Paul Waymack to our distinguished team of scientific advisors and look forward to their contributions. We strongly believe that enlisting and consulting with highly competent scientific advisors, especially as we enter into a critical period, is key to our future success. We have already been working closely with both of these advisors in our preparation of our IND submission for Annamycin and it's an honor to have them now formally join our SAB.  Clearly their deep scientific expertise at large pharmaceutical companies, top Universities and hospitals, as well as their contacts and overall knowledge base will be extremely helpful."

In other sector developments of note in the market: 

Apricus Biosciences, Inc. (NASDAQ: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, yesterday announced that Mexico has granted Apricus` commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction.

CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) and Eli Lilly and Company (LLY) yesterday announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.  CoLucid Pharmaceuticals is a public biopharmaceutical company developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine. CoLucid has completed the first of two pivotal Phase 3 trials. A data read-out for the second Phase 3 trial, SPARTAN, is expected in the second half of 2017. If this trial is positive, submission of lasmiditan for U.S. regulatory approval could occur in 2018.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced this week the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed a significant improvement in overall symptoms of Tourette syndrome as evidenced by the Clinical Global Impression of Change (p=0.015), the pre-specified primary endpoint, the change-from-baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 was not met (p=0.18). Adverse events were dose dependent and consistent with earlier clinical studies.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

DISCLAIMER:  MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  MNU is NOT affiliated in any manner with any company mentioned herein.  MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  MNU is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Moleculin Biotech, Inc., by the company.  MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:

Media Contact email:  info@marketnewsupdates.com - +1(561)325-8757


'/>"/>
SOURCE MarketNewsUpdates.com
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Surgery Patient Gains Trump Big Pharma Losses, Anesthesia Drug Use Reduced Up To 30%
2. Halting or reducing opioids prior to hip or knee replacement surgery linked to fewer complications, improved outcomes and reduced post-surgical opioid use
3. Global Vascular and Non-Vascular Stents Market 2015-2021 - Threats for the Stents Market Include Reduced Reimbursement, Alternative Procedures and Stringent Regulations for Stent Approval
4. Researchers Show That Combining Intensity Modulated Radiation Therapy With Chemo-Radiation Offers Long-Term Benefits And Reduced Side Effects For Oropharyngeal Cancer Patients
5. Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners
6. New Data Show Improved Survival, Reduced Cardiovascular Hospital Readmissions, and Increased Transplantation on Home Hemodialysis with the NxStage System One
7. New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases
8. Salix Pharmaceuticals Ltd. Investigated by Block & Leviton LLP After The Company Announces Resignation Of Its Chief Financial Officer And Reduced Financial Forecasts
9. Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE
10. NeuroAiDTM, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke
11. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... DIEGO (PRWEB) , ... June 11, 2019 , ... ... global Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology ... of Wei Chen, Ph.D as the company's new Chief Executive Officer (CEO). Dr ...
(Date:6/6/2019)... ... June 06, 2019 , ... ... announced today that it was selected as the “Best Patient Registration and Scheduling ... top clinical and health administration platforms and products in the healthcare industry. ...
(Date:6/6/2019)... ... June 05, 2019 , ... The number of neonatal therapists ... earn the designation of Certified Neonatal Therapist (CNT). It highlights specialized professionals who ... the Neonatal Therapy National Certification Board (NTNCB). Today, more than 300 professionals internationally ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... Many people with back pain that radiates ... term itself is widely misunderstood and so are its treatments, according to Kaliq Chang, ... , “Sciatica is commonly used to describe nerve-like pain traveling down ...
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of ... in Health Informatics (MSHI ) degree program to address the growing need for professionals ... is part of a larger effort for SHRS to bring more graduate degrees online. ...
(Date:6/13/2019)... NEW YORK (PRWEB) , ... ... ... of 3D printing—including medical and dental implants, additive manufacturing (AM)-enabled tissue fabrication, ... Every day, physicians are using AM medical technologies to improve patient care. ...
(Date:6/12/2019)... , ... June 12, 2019 , ... ... causing relationships with caregivers and dementia patients to deteriorate. , Researchers from ... included a survey with professional caregivers who care for people who have dementia ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... quality assurance expert with more than 25 years of experience in quality systems ... all classes of medical devices, has joined NDA Partners as an Expert Consultant. ...
Breaking Medicine News(10 mins):